BMS Positions Cobenfy as Safer Alternative Ahead of Pivotal Alzheimer’s Psychosis Readout

BMS Anticipates Pivotal Cobenfy Alzheimer's Psychosis Data After Trial Delay

Bristol Myers Squibb is positioning its schizophrenia drug, Cobenfy, as a potentially safer alternative for Alzheimer's disease psychosis, an indication affecting 30-50% of the 7 million diagnosed Alzheimer's patients. The company anticipates pivotal Phase 3 ADEPT-2 study data later this year, following a delay in late 2025 due to "irregularities" at some study sites. Cobenfy, acquired through the $14 billion Karuna Therapeutics acquisition in late 2023 and approved for schizophrenia in September 2024, is highlighted for not carrying the boxed warnings associated with many current antipsychotics or amyloid-targeting Alzheimer's therapies.

• Bristol Myers Squibb emphasizes Cobenfy's safety as a key advantage for Alzheimer's disease psychosis, particularly in the elderly population. Unlike many antipsychotic drugs that carry boxed warnings for increased death risk in elderly dementia patients, or amyloid-targeting therapies like Leqembi and Kisunla with warnings for amyloid-related imaging abnormalities, Cobenfy does not have such a boxed warning. This positions it as a potentially safer option for a patient group with significant unmet medical need.
• The pivotal Phase 3 ADEPT-2 study, evaluating Cobenfy for Alzheimer's disease psychosis, is expected to deliver data later this year. The readout was initially anticipated by the end of 2025 but was delayed due to "irregularities" identified at a small number of study sites. This upcoming data is crucial for BMS's strategy to expand Cobenfy's indications beyond its current approval for schizophrenia, addressing a significant unmet need.
• Cobenfy, originally known as KarXT, was central to Bristol Myers Squibb's $14 billion acquisition of Karuna Therapeutics in late 2023. The drug received FDA approval for schizophrenia in September 2024. Despite some initial commercial struggles and underwhelming analyst uptake, Cobenfy contributed $56 million to BMS's Q1 2026 revenue, narrowly beating consensus estimates, and is considered a key next-generation growth driver for the company.

The Critical Need for Safer Alzheimer’s Disease Psychosis Treatments

Current treatment approaches for Alzheimer's disease psychosis face substantial challenges that limit their clinical utility and patient safety. These limitations span from fundamental efficacy issues to serious safety concerns that have prompted regulatory warnings. The complexity of neuropsychiatric symptoms in dementia further complicates therapeutic targeting and outcomes.

• Limited efficacy and treatment response: Pharmacological treatments for neuropsychiatric symptoms demonstrate limited effectiveness due to lack of efficacy, with recent studies showing some patients receiving active treatments exhibit no superior response compared to placebo, and randomized controlled trials indicating that symptom severity reduces in a time-dependent manner regardless of active intervention.

• Serious safety profile and FDA warnings: Antipsychotics carry significant mortality risks, with FDA black box warnings issued for both atypical (2005) and typical (2008) antipsychotics due to increased all-cause mortality in elderly dementia patients, including elevated risks of cerebrovascular events, stroke (adjusted OR 1.60), and pneumonia as a frequently reported cause of death.

• Narrow therapeutic window and limited symptom coverage: Antipsychotics represent the only available treatment for behavioral and psychological symptoms of dementia but are only effective and safer in short-term use (6-12 weeks), can manage aggression but not agitation, and cannot control pain, creating gaps in comprehensive symptom management.

• Complex symptom presentation challenges targeted therapy: The concurrence of multiple sub-symptoms within neuropsychiatric symptom clusters makes it difficult to target individual symptoms exclusively, complicating treatment selection and outcome measurement in clinical practice.

• Absence of disease-modifying approaches: Current therapeutic efforts focus primarily on symptom management through neurotransmitter restoration, protein aggregate removal, or symptomatic treatment, with no available disease-modifying therapies capable of stopping or reversing neurodegeneration beyond maintaining mental function and managing behavioral symptoms.

• Regulatory approval gaps: No psychotropic medications have received FDA approval specifically for Alzheimer's disease psychosis treatment, with atypical antipsychotics remaining unapproved for dementia-associated psychosis despite being the most commonly used intervention for this indication.

Cobenfy’s Position in the Evolving Alzheimer’s Disease Psychosis Landscape

The treatment landscape for Alzheimer's disease psychosis has experienced significant evolution over the past five years, marked by both regulatory milestones and persistent therapeutic gaps. Brexpiprazole emerged as a breakthrough treatment, receiving FDA approval as the first medication specifically indicated for Alzheimer's-related agitation. Meta-analysis of three randomized controlled trials comprising 1,048 patients demonstrated that brexpiprazole significantly improved Cohen-Mansfield Agitation Inventory total scores at any dose (MD -3.05; 95% CI -5.12, -0.98; p<0.01) over 12 weeks, with the 2 mg dose showing greater improvement (MD -4.36; 95% CI -7.02, -1.70; p<0.01). Despite this regulatory success, brexpiprazole's therapeutic profile indicates only modest efficacy with high safety, and notably, no drugs have yet been approved for treating psychosis specifically in Alzheimer's disease, highlighting the critical unmet medical need.

The pipeline landscape shows promising diversification with multiple investigational agents advancing through late-stage development. Xanomeline-trospium is currently in phase 3 trials specifically for Alzheimer's disease psychosis, while dextromethorphan-bupropion and dexmedetomidine are being evaluated in phase 3 trials for agitation. Additional compounds under investigation include pimavanserin, nabilone, AXS-05, and AVP-786 for psychiatric manifestations of Alzheimer's disease. Drug combinations designed to inhibit dextromethorphan metabolism peripherally have shown positive Phase 2 results, and cannabinoids have similarly demonstrated encouraging Phase 2 outcomes as they advance to Phase 3 testing.

Recent clinical research has also emphasized the importance of non-pharmacological interventions and revealed concerning findings about current antipsychotic utilization patterns. A nationwide observational study spanning 2012-2017 found that decreases in nursing home antipsychotic use did not improve resident mortality or hospitalization outcomes (adjusted death risk RR 1.01; 95% CI 1.00, 1.01), suggesting that intensive initiatives focused predominantly on reducing antipsychotic use may be ineffective without safe and effective alternatives. Music therapy has gained recognition as a first-line treatment for neuropsychiatric symptoms, though implementation remains challenging due to enormous heterogeneity in practice approaches and lack of standardized protocols. The field has also seen setbacks in disease-modifying approaches, with solanezumab failing to demonstrate meaningful clinical benefits across seven trials involving 4,181 participants, showing no significant reduction in cognitive decline or functional improvement.

Cobenfy's Bid to Redefine Alzheimer's Psychosis Treatment

The pharmaceutical landscape for neuropsychiatric disorders is on the cusp of a significant shift, with the muscarinic M1/M4 receptor agonist, Cobenfy (xanomeline-trospium), poised to potentially redefine treatment paradigms beyond schizophrenia. Recently approved for schizophrenia, where it demonstrated significant reductions in positive and negative symptoms with a distinct safety profile, Cobenfy is now being strategically positioned for Alzheimer's disease psychosis (ADP). This move is particularly compelling given the substantial unmet need in ADP, a debilitating condition affecting a large proportion of Alzheimer's patients.

Current pharmacological interventions for psychosis in dementia are often limited by modest efficacy and significant safety concerns, including increased risks of cerebrovascular events and mortality, leading to boxed warnings for many traditional antipsychotics. Cobenfy's non-dopaminergic mechanism of action offers a crucial advantage, as it avoids the extrapyramidal symptoms, weight gain, and other metabolic side effects commonly associated with conventional dopamine-blocking agents. This differentiated safety profile could make it a highly attractive option for a vulnerable elderly population, where tolerability is paramount.

However, the path forward is not without its challenges. The reported "irregularities" in some sites of the pivotal Phase 3 ADEPT-2 study introduce an element of uncertainty that could impact the trial's timeline or eventual outcome. Furthermore, while generally well-tolerated, Cobenfy is associated with cholinergic adverse events such as nausea, constipation, and dry mouth, which, though typically mild to moderate, could affect adherence in some patients. Specific contraindications for individuals with hepatic or renal dysfunction also warrant careful consideration, as these comorbidities are prevalent in older adults. Despite these considerations, the potential for Cobenfy to offer a safer, more effective treatment for ADP represents a renewed hope, validating a novel therapeutic pathway and potentially paving the way for further innovation in non-dopaminergic approaches across a broader spectrum of neuropsychiatric conditions.